Example: Heart Attack

Clinical Trials on Polyradiculoneuropathy

Total 109 results

NCT01625182

Completed

Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
NCT04051944

Enrolling by invitation

A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
NCT03861481

Active, not recruiting

A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
NCT04529291

Not yet recruiting

InertiaLocoGraphy as a Biomarker of Immunoglobulin Therapy Efficacy in Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
NCT01017159

Completed

Subcutaneous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Conditions: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
NCT04742374

Not yet recruiting

Effects of Single Plasma Exchange and Double Filtration Plasmapheresis (DFPP) on Peripheral Lymphocyte Phenotypes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Conditions: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
NCT03967899

Active, not recruiting

Study of Electrical Prognostic Factors of Response to Intravenous Immunoglobulin Treatment in Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
NCT00099489

Completed

Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
NCT02892890

Unknown status

Exploratory Study of Predictive Markers of the Therapeutic Response in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Treated With Intravenous Immunoglobulin

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
NCT02549170

Recruiting

Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDP

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
NCT00305266

Completed

Study of CIDP Patients During IVIG Treatment

Conditions: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
NCT02955355

Recruiting

Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
NCT02293460

Completed

Efficacy and Safety Study of I10E in Treatment of Patients With CIDP

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
NCT02317562

Terminated

Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
NCT02017769

Completed

MRI in Diagnosing and Monitoring CIDP

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
NCT04356781

Not yet recruiting

Do IgG Level Variations in CIDP and MMN Patients Following Initial Intravenous IVIg Treatment Correlate With Ultimate Dosing

Conditions: Multifocal Motor Neuropathy (MMN); Chronic Inflammatory Demyelinating Polyradiculoneuropathy
NCT04249752

Recruiting

Biomarkers in Polyradiculoneuropathies

Conditions: Guillain-Barre Syndrome; CIDP
NCT02271724

Unknown status

sCD163 & CD19 as Candidate Biomarkers in CIDP and MMN

Conditions: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
NCT03864185

Active, not recruiting

The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
NCT01225276

Terminated

Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
NCT01757574

Withdrawn

Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD)

Conditions: Chronic Inflammatory Demyelinating Neuropathy
NCT02629796

Recruiting

Biomark Study: Predict Intravenous Immunoglobulin Responders in Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Conditions: CIDP
NCT00004939

Completed

Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy

Conditions: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
NCT00004772

Completed

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy

Conditions: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
NCT00004286

Completed

Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy

Conditions: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating